Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666926 · ClinicalTrials.gov registry record · Phase 1
Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
A Phase 1 study, sponsored by Verastem.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT00666926 is a Phase 1 study that has completed, run by Verastem. The registered enrollment target is 99 participants.
The verdict
NCT00666926, a Phase 1 study, has completed, sponsored by Verastem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase (FAK) inhibitor PF-00562271 in patients with positive Positron Emission Tomography \[PET\] scans due to advanced non-hematologic malignancies, including pancreatic, head and neck, and prostatic neoplasms, and patients with other malignancies appropriate for serial biopsy. Screening consists of a Fluorodeoxyglucose Positron Emission Tomography \[FDG-PET\] and tumor imaging, medical history, physical examination, Eastern Cooperative Oncology Group \[ECOG\] performance status, blood draws, a pregnancy test for female patients of childbearing potential. Treatment consists of PF00562271 tablets continued until progression of disease, unacceptable toxicity, or patient request. Evaluations for bioactivity are measured by serial FDG-PET and blood tests for biomarkers related to FAK and PYK2 kinase activities.
Interventions
- DRUG PF00562271
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2005-12 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00666926
The ClinicalTrials.gov registry entry for NCT00666926 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verastem, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF00562271 is the first listed.
NCT00666926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00666926 about?
NCT00666926 is a clinical study titled "Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms". Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase (FAK) inhibitor PF-00562271 in patients with positive Positron Emission Tomography \[PET\] scans due to advanced non-hematologic malignancies, including pancreatic, head and neck, and prostatic neoplasms, and p...
What is the current status of trial NCT00666926?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2005-12. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00666926?
The interventions under investigation include: PF00562271 (DRUG).
Who is sponsoring clinical trial NCT00666926?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.